Celera (NASDAQ:CRA) today announced the appointment of Scott K. Milsten as Vice President, General Counsel and Corporate Secretary, effective immediately. Mr. Milsten will report to Kathy Ordoñez, Celera’s Chief Executive Officer.

Mr. Milsten was most recently Deputy General Counsel for Gen-Probe Incorporated (NASDAQ:GPRO). In this capacity, he managed corporate governance and securities compliance, and structured and negotiated strategic transactions. He also oversaw a variety of intellectual property and human resource matters. Prior to Gen-Probe, Mr. Milsten practiced corporate law with the law firm of Latham & Watkins LLP, where he specialized in mergers and acquisitions, proxy contests and securities offerings for life science and technology companies.

Mr. Milsten received his B.A. from Duke University, Durham, NC, and his Juris Doctor degree from the University of Pennsylvania, PA.

“Scott adds critical corporate governance expertise to the management team for our newly independent company,” said Kathy Ordoñez, Chief Executive Officer of Celera. "With a strong track record in molecular diagnostics and the life sciences industry, we expect Scott to become a key contributor as we move Celera forward.”

About Celera

Celera is a healthcare business delivering personalized disease management through a combination of products and services incorporating proprietary discoveries. Berkeley HeartLab, a subsidiary of Celera, offers services to predict cardiovascular disease risk and improve patient management. Celera also commercializes a wide range of molecular diagnostic products through its strategic alliance with Abbott and has licensed other relevant diagnostic technologies developed to provide personalized disease management in cancer and liver diseases. Information about Celera Corporation, including reports and other information filed by the company with the Securities and Exchange Commission, is available at http://www.celera.com.